Safety and Activity of the First-in-Class Sym004 Anti-EGFR Antibody Mixture in Patients with Refractory Colorectal Cancer
Year: 2015
Type: article
Study design: Clinical Trial
Source: Cancer Discovery
Authors: Rodrigo Dienstmann, Amita Patnaik, Rocio Garcia-Carbonero, Andrés Cervantes, Marta Benavent, Susana Roselló, Bastiaan B.J. Tops, Rachel S. van der Post, Guillem Argilés, Niels J.Ø. Skartved, Ulla H. Hansen, Rikke Hald, Mikkel W. Pedersen, Michael Kragh, Ivan D. Horak, Stephan Braun, Eric Van Cutsem, Anthony W. Tolcher, Josep Tabernero
Institutions: Universitat Autònoma de Barcelona, Sage Bionetworks, Fred Hutch Cancer Center, Vall d'Hebron Hospital Universitari, Vall d'Hebron Institute of Oncology, South Texas Accelerated Research Therapeutics, Consejo Superior de Investigaciones Científicas, Instituto de Biomedicina de Sevilla, Hospital Universitario Virgen del Rocío, Universidad de Sevilla, Universitat de València, Radboud University Medical Center, Symphogen (Denmark), Universitair Ziekenhuis Leuven, KU Leuven
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
Funders: European Commission, Symphogen
OpenAlex ID: W2130584549
